230,000 Additional RSV Shots for Infants to be Available by January

Move follows pressure from Biden administration on drug manufacturers amid nationwide shortage and peak RSV season.

An additional 230,000 doses of the respiratory syncytial virus (RSV) shot for infants will be available by January, following pressure from the Biden administration on drug manufacturers.
The move comes amid a nationwide shortage of the shots, which has worsened since October, causing concern as RSV season begins to peak.
The White House has been holding high-level meetings with manufacturers like AstraZeneca and Sanofi to boost supplies of their RSV shots.
The additional doses were originally reserved for the 2024 RSV season in the Southern Hemisphere and will be replenished before that season starts.
The RSV shot, approved this summer, is the first opportunity to protect infants against RSV, the leading cause of hospitalization for infants during their first year of life.